CVKD Latest Press Releases

-- October 7, 2026 --

Cadrenal Therapeutics Retains Tungsten Advisors to Lead Formal Strategic Process to Maximize Value of its Orphan Thrombo-Inflammatory Therapeutics Globe Newswire 7:00 AM

-- September 21, 2026 --

Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2026 Investor Conference Globe Newswire 4:30 PM

-- September 3, 2026 --

Cadrenal Therapeutics to Participate in H.C. Wainwright's 28th Annual Global Investment Conference Globe Newswire 8:00 AM

-- August 31, 2026 --

Cadrenal Therapeutics Announces Positive Outcome from FDA Type D Meeting for Phase 3 Registration Study of CAD-1005 in Heparin-Induced Thrombocytopenia Globe Newswire 8:00 AM

-- August 13, 2026 --

Cadrenal Therapeutics Reports Second Quarter 2026 Financial Results; Provides a Corporate Update on the Cardiac Acute Critical Care Franchise and the Strategic Partnering Process Globe Newswire 4:15 PM

-- August 3, 2026 --

Cadrenal Therapeutics Solidifies Multi-Indication Strategy for CAD-1005 in Cardiac Acute Critical Care Following Competitor's Phase 3 Discontinuation Globe Newswire 8:30 AM

-- July 21, 2026 --

Cadrenal Therapeutics Launches Partnering Process as Its Cardiac Acute Critical Care Assets Advance to Transaction Readiness Following Landmark ISTH Data Presentation Globe Newswire 8:00 AM

-- July 13, 2026 --

Cadrenal Therapeutics' Late-Breaking Phase 2 Data Demonstrate Greater Than 25% Reduction in Thrombotic Events in HIT for First-in-Class 12-LOX Inhibitor CAD-1005 at ISTH 2026 Congress Globe Newswire 9:00 AM

-- June 30, 2026 --

Cadrenal Therapeutics Announces up to $8.8 Million Private Placement Priced At-The-Market Under Nasdaq Rules Globe Newswire 8:00 PM

-- June 24, 2026 --

Cadrenal Therapeutics Announces Selection of CAD-1005 Phase 2 Study for Late-Breaking Oral Presentation at ISTH 2026 Congress Globe Newswire 8:00 AM

-- June 18, 2026 --

Cadrenal Therapeutics to File for FDA Rare Pediatric Disease Designation for Tecarfarin in Kawasaki Disease Globe Newswire 9:00 AM

-- June 15, 2026 --

Cadrenal Therapeutics Advances Multi-Indication Strategy for CAD-1005; Launches Phase 2a Acute Kidney Injury (CSA-AKI) Clinical Plan to Accelerate Pharma Partnering at Upcoming BIO 2026 Globe Newswire 8:30 AM

Market Data Delayed 15 Minutes